November 23, 2021
2 min watch
Save
VIDEO: Xipere to be available in first quarter of 2022
NEW ORLEANS — In this Healio Video Perspective from the AAO meeting, Yolande Barnard, vice president and general manager, U.S. Pharmaceuticals, Bausch + Lomb, discusses Xipere (triamcinolone acetonide injectable suspension).
The therapy, from Bausch + Lomb and Clearside Biomedical, was recently approved as a suprachoroidal injection for the treatment of macular edema secondary to uveitis, Barnard said.